Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas

Joseph RoswarskiCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA; ;Walter Reed National Military Medical Center, Bethesda, MD, USA;

http://orcid.org/0000-0002-1470-8814

Mark RoschewskiCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;

Andrea LucasCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;

Christopher MelaniCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;

Stefania PittalugaLaboratory of Pathology, National Cancer Institute, Bethesda, MD, USA

Elaine S. JaffeLaboratory of Pathology, National Cancer Institute, Bethesda, MD, USA

Seth M. SteinbergCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;

Thomas A. WaldmannCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;

Wyndham H. WilsonCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Correspondence[email protected]

show all

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas

ICMJE Form for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas

ICMJE Form for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date